Business
OncBioMune Preparing to Initiate Trials of Novel Therapeutic Ovarian Cancer Vaccine
OncBioMune Preparing to Initiate Trials of Novel Therapeutic Ovarian Cancer Vaccine.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\n\n BATON ROUGE, La., Oct. 17, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (\"OncBioMune\" or the \"Company\"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer vaccine technology, targeted cancer therapies and commercialization of a portfolio of products internationally, is pleased to inform shareholders that the company has begun the process to initiate clinical studies of OvcaVax for ovarian cancer.  Built upon the same platform as ProscaVax, the Company’s novel therapeutic vaccine for prostate cancer, OvcaVax is therapeutic ovarian cancer vaccine consisting of a combination of cancer antigen 125 (CA-125), interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).\n In the coming weeks, OncBioMune management will be scheduling CA-125 manufacturing under cGMP standards and conducting meetings with contract research organization Theradex Oncology to discuss trial protocol, site location and trial budget.  Based upon initial dialogue, the intentions are for a small study enrolling approximately 20 ovarian cancer patients at varying stages of disease to receive OvcaVax in an adjuvant setting following a surgical procedure.  Endpoints will include safety, progression-free survival and overall survival.  OncBioMune also intends to pursue select U.S. Food and Drug Administration pathways, such as Orphan Drug designation or Fast Track designation, that can expedite development of OvcaVax and provide extra intellectual property protection should OvcaVax successfully complete clinical trials and be approved for commercialization in the future. “During our in-house trials, we previously treated four ovarian cancer patients with advanced disease with no signs of toxicity.  That data combined with hundreds of other patients receiving vaccinations from the platform technology has us confident in the safety profile of OvcaVax,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune.  “Recently, we collected very compelling data on ProscaVax eliciting an increased immune response and slowing tumor progression in prostate cancer and believe the same is possible in late-stage ovarian cancer, where women are left with very few therapeutic options.  I firmly believe that immunothe...